Sinovac Pharmaceutical won the "Most Growing Listed Company in Biomedicine" award

On December 28, the "11th China Listed Companies Summit Forum" series of activities hosted by the domestic mainstream financial media - Daily Economic News was grandly held online, during which the annual honor ceremony of China's capital market - "2022 The 12th China Listed Companies Word of Mouth List" was released
.
Sinovac Biopharmaceutical Co.
, Ltd.
(stock code: 688136) won the "Most Growing Listed Company in Biomedicine" award
for its good product reputation, R&D innovation and commercialization advantages, and brand value accumulated over the years.

As an important annual event in the domestic capital market, the Listed Companies Summit Forum and the Word-of-Mouth List of Chinese Listed Companies are influential activities in the industry, and are also important communication platforms
between investors and listed companies.
After more than 3 months of selection, after four major links of public nomination, big data screening, model screening and institutional + public voting, 15 blockbuster awards
on the word-of-mouth list were born.

The award of "Most Growing Listed Company in Biomedicine" highlights Sinovac's comprehensive strength, sustainable development ability and social responsibility in the biopharmaceutical industry, and fully reflects the high recognition
of the capital market for the company's high-quality operation and management, market investment value and good brand image.

In 2022, Sinovac Pharmaceutical continued to accumulate scientific and technological innovation strength and made a number of breakthroughs
.
The company's series of pipelines around the anti-virus layout have made important progress: the anti-new coronavirus small molecule oral drug SHEN26 capsules have entered clinical phase II, human interferon α1b inhalation solution, human interferon α2b spray, human interferon α2b effervescent capsules and other products have been approved for clinical trials, and the research and development strength is remarkable
.
In addition, Sinovac's research projects also include pegylated human granulocyte stimulating factor injection, long-acting growth hormone, etc.
, and has laid out the research and development of animal genetic engineering vector vaccines and synthetic biology in advance, and the prospects are highly anticipated
.

Among them, the market is particularly concerned about the SHEN26 project, and its IIT research results show that SHEN26 capsules can prevent virus replication, shorten the nucleic acid conversion time of patients with mild and common new coronavirus infection, and the antiviral effect is obvious, and the safety performance is ideal.

Recently, the new coronavirus pneumonia was officially renamed as the new coronavirus infection, and the state also issued a notice to implement "Class B tube"
for the new coronavirus infection from January 8, 2023.
From the epidemic situation, Omicron variant has become the global epidemic dominant strain, due to the Omicron virus spread widely, fast speed, the current number of domestic infections is large, so the future anti-virus market will become a long-term demand market, Sinovac Pharmaceutical holds interferon and SHEN26 two antiviral product lines, market growth potential is huge
.
It is reported that SHEN26 is carrying out phase II clinical research in Shenzhen Third People's Hospital, Shijiazhuang Fifth Hospital and Shenzhen Longhua People's Hospital
.

At the same time, with the upsurge of domestic pharmaceutical companies going overseas, Sinovac Pharmaceutical has also accelerated the pace of
internationalization.
Relying on more than 20 years of accumulated commercialization experience, successful overseas commercialization practice, high-quality overseas commercialization resources, and rapid overseas registration capabilities, the company has established strategic cooperation with domestic and foreign biotechnology companies, and obtained a number of domestic and foreign commercialization rights and interests: bevacizumab has exclusive commercialization licenses in all countries and regions around the world except China, the European Union (subject to EU member states in 2021), the United Kingdom, the United States, and Japan; Infliximab (class stop) exclusive promotion rights in all countries and regions except Japan, Europe and North America; Commercialization rights of albumin paclitaxel other than the U.
S.
market; The commercialization rights of adalimumab in many overseas countries, as well as the recently signed exclusive commercial license cooperation agreement
for liraglutide injection in 17 countries in overseas emerging markets.

Focusing on the vision of "a leader in high-quality biopharmaceuticals", Sinovac will base itself on the field of biotechnology and vigorously grasp the introduction of products by expanding in-depth cooperation with advanced enterprises at home and abroad; At the same time, we will firmly adhere to R&D and innovation, absorb technical talents, and accelerate the R&D of various pipelines; Actively cultivate new industries to continuously enrich business segments, optimize product structure, enhance the company's core competitiveness, and enhance the company's high-quality development momentum
.

It is understood that the theme of the selection activity of the word-of-mouth list of Chinese listed companies is "Characteristic shaping, value return", aiming to recognize listed companies
that lead scientific and technological innovation and future trends, and actively promote the development of the industry.
Since 2011, the event has been held for 12 consecutive years, with good credibility and influence, and has become one of
the important selections with far-reaching influence in the industry.

The leader of high-quality biopharmaceuticals has always been Sinovac's tireless pursuit
.
At the same time, it is also Sinovac's responsibility
to accept the review from investors, establish a valuable market reputation, create more value, and actively promote the healthy development of China's capital market.